VEGFA and head and neck squamous cell carcinoma: These studies highlighted both, the value of VEGF as biomarker (despite VEGF was measured in serum) as they were able to demonstrate in 1st line treatment of R/M HNSCC a reduction in median VEGF concentrations from baseline 547.7 ng/L to 59.45 ng/L post treatment along with VEGF-targeting by bevacizumab [32] and the improved outcome achieved through VEGF targeting [22].